EstroTep 500 MBq/mL, solution injectable, ELACESTRANT, EXEMESTANE, ELACESTRANT
UID 4270
Phase 2 small_molecule active
Quick answer
EstroTep 500 MBq/mL, solution injectable, ELACESTRANT, EXEMESTANE, ELACESTRANT for Metastatic hormone receptor-positive/HER2-negative breast cancer is a Phase 2 program (small_molecule) at Istituto Gentili S.r.l. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Istituto Gentili S.r.l.
- Indication
- Metastatic hormone receptor-positive/HER2-negative breast cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active